Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
As many in the field have said before, what we really need are antifungals with a truly novel MoA, not minor changes to well-established classes.[1] There is a shortage of new antifungals for invasive disease. Small improvements in PK will hardly move the field forward or excite investors to engage. Our current Continue reading The Antifungal Landscape – 2
A new Guideline for the treatment of cUTI just arrived.[1] First, we are glad that this somewhat mundane topic receives the attention it deserves. UTIs are often downplayed as minor infections, but the cUTI variety should not be taken lightly. Many patients still are admitted with life-threatening infections, so prompt Continue reading NEW IDSA cUTI GUIDELINE
New medical and science journals pop up in our mailbox on a biweekly basis. Offers to join as Editor, solicitation for articles based on past publications, invitations for subject reviews come as unsolicited emails. Medical publication houses, old and new, are expanding, adding more and more subspecialties to their established Continue reading JOURNAL BUSINESS vs EDITORIAL OVERSIGHT